Latest news

• GSK seeks EU approval for Trelegy in adult asthma patients

  Triple respiratory drug Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is already approved in the EU and US for use in chronic obstructive pulmonary disease (COPD) patients, although GSK is now keen ... GSK’s respiratory business has

• GSK considers more divestments to help R&D push

  She said it was encouraging that in the year that generic competition really bit hard into sales of GSK’s longstanding respiratory blockbuster Advair/Seretide (fluticasone propionate/salmeterol), the group was

• Novartis strengthens case for its combination asthma drug

  However, it was still able to establish its next-generation of respiratory products – this includes Trelegy (vilanterol/umeclidinium/ fluticasone furoate), which brought in £139 in  Q3 and Nucala (mepolizumab), which brought

• GSK boosts outlook thanks to strong respiratory and vaccine sales

  New launches for respiratory products Nucala (mepolizumab) and Trelegy (vilanterol/umeclidinium/ fluticasone furoate) helped boost revenues in this area, bringing in £203m and £139m respectively.

• AZ builds case for its COPD triple as it chases GSK’s Trelegy

  After a slow start, Trelegy (vilanterol/umeclidinium/ fluticasone furoate) is showing signs of gathering momentum, with sales more than doubling to around $250m in the first half of this year.